Dr. Matthew Hogenmiller, M.D.
What this data tells you about Dr. Hogenmiller
Dr. Matthew Hogenmiller is a rheumatology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Hogenmiller performed 49,493 Medicare services across 2,776 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hogenmiller received a total of $9,693 from 39 pharmaceutical and/or device companies across 501 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hogenmiller is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) | 40,400 | $4 | $15 |
| Denosumab injection (Prolia/Xgeva) | 4,380 | $18 | $69 |
| Office visit, established patient (30-39 min) | 577 | $90 | $377 |
| Comprehensive metabolic blood panel | 565 | $10 | $32 |
| Complete blood count (CBC) with differential | 465 | $7 | $23 |
| Blood draw (venipuncture) | 453 | $8 | $27 |
| C-reactive protein test (inflammation marker) | 450 | $5 | $15 |
| Sed rate test (inflammation marker) | 448 | $3 | $8 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 283 | $56 | $218 |
| Measurement of complement (immune system proteins), antigen, | 200 | $11 | $36 |
| Vitamin D level test | 168 | $29 | $89 |
| New patient office visit (45-59 min) | 107 | $116 | $492 |
| Uric acid level test | 99 | $4 | $14 |
| Screening test for antibody to noninfectious agent | 98 | $11 | $36 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 93 | $17 | $54 |
| Measurement of antibody for rheumatoid arthritis assessment | 91 | $12 | $39 |
| Rheumatoid factor level | 86 | $5 | $17 |
| Screening test for autoimmune disorder | 75 | $12 | $36 |
| Magnesium level test | 68 | $7 | $20 |
| Phosphate level test | 67 | $5 | $14 |
| Office visit, established patient (20-29 min) | 53 | $63 | $267 |
| Creatine kinase (cardiac enzyme) level, total | 32 | $6 | $20 |
| Automated urinalysis | 30 | $2 | $7 |
| Hepatitis b core antibody measurement | 29 | $11 | $36 |
| Hepatitis b surface antibody measurement | 29 | $10 | $32 |
| Hepatitis c antibody measurement | 29 | $13 | $43 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 29 | $9 | $31 |
| Urinalysis with microscopic exam | 21 | $3 | $10 |
| Ferritin level test (iron stores) | 19 | $13 | $41 |
| Iron level test | 19 | $6 | $19 |
| Iron binding capacity test | 19 | $9 | $26 |
| New patient office visit (30-44 min) | 11 | $79 | $331 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Hogenmiller is a mixed practice specialist, with above-average Medicare volume (top 23% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Hogenmiller experienced with certolizumab injection (cimzia)?
Does Dr. Hogenmiller receive payments from pharmaceutical companies?
How do Dr. Hogenmiller's costs compare to other rheumatologists in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology